Fundraising Fox

Abingworth2022 Investments

2 investments dated 2022 · listed companies and verified rows first · show all

Entact Bioentactbio.comSeries A · Dec 2022 · $81M

Entact is a drug discovery company developing treatments for patients.

BiotechDeep TechWatertown, US

Victoria Richon(Executive Officer, Director, Promoter)inRuben Tommasi(Chief Scientific Officer)Michael Gutch(Chief Operating Officer)Alon Lazarus(Director)

BoardAndrew Sinclair(Director)Anna French(Director)in

Co-investorsvenBio PartnersvenBio Global Strategic

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Launch Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.